A Randomized Trial of Nafamostat for Covid-19

NEJM Evid. 2023 Nov;2(11):EVIDoa2300132. doi: 10.1056/EVIDoa2300132. Epub 2023 Oct 18.


A Randomized Trial of Nafamostat for Covid-19Nafamostat mesylate is a potent in vitro antiviral that inhibits the host transmembrane protease serine 2 enzyme used by SARS-CoV-2 for cell entry. Morpeth et al report the results of an open-label randomized clinical trial of nafamostat for noncritically ill patients with Covid-19.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Benzamidines
  • COVID-19*
  • Guanidines / pharmacology
  • Humans
  • SARS-CoV-2


  • nafamostat
  • Guanidines
  • Benzamidines